Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Journal of Environmental Pathology, Toxicology and Oncology
IF: 1.241 5-Year IF: 1.349 SJR: 0.519 SNIP: 0.613 CiteScore™: 1.61

ISSN Print: 0731-8898
ISSN Online: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2017018341
pages 151-158

Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma

Venugopal Vinod Prabhu
Department of Biochemistry, University of Madras, Guindy campus, Chennai−600025, Tamil Nadu, India
Niranjali Devaraj
Department of Biochemistry, University of Madras, Guindy campus, Chennai−600025, Tamil Nadu, India

ABSTRACT

Lung cancer is responsible for 1.6 million deaths. Approximately 80%−85% of lung cancers are of the non-small-cell variety, which includes squamous cell carcinoma, adenocarcinoma, and large-cell carcinoma. Knowing the stage of cancer progression is a requisite for determining which management approach−surgery, chemotherapy, radiotherapy, and/or immunotherapy−is optimal. Targeted therapeutic approaches with antiangiogenic monoclonal antibodies or tyrosine kinase inhibitors are one option if tumors harbor oncogene mutations. Another, newer approach is directed against cancer-specific molecules and signaling pathways and thus has more limited nonspecific toxicities. This approach targets the epidermal growth factor receptor (EGFR, HER-1/ErbB1), a receptor tyrosine kinase of the ErbB family, which consists of four closely related receptors: HER-1/ErbB1, HER-2/neu/ErbB2, HER-3/ErbB3, and HER-4/ErbB4. Because EGFR is expressed at high levels on the surface of some cancer cells, it has been recognized as an effective anticancer target. EGFR-targeted therapies include monoclonal antibodies (mAbs) and small-molecule tyrosine kinase inhibitors. Tyrosine kinases are an especially important target because they play an important role in the modulation of growth factor signaling. This review highlights various classes of synthetically derived molecules that have been reported in the last few years as potential EGFR-TK inhibitors (TKIs) and their targeted therapies in NSCLC, along with effective strategies for overcoming EGFR-TKI resistance and efforts to develop a novel potent EGFR-TKI as an efficient target of NSCLC treatment in the foreseeable future.


Articles with similar content:

Review of Triple Negative Breast Cancer and the Impact of Inducible Nitric Oxide Synthase on Tumor Biology and Patient Outcomes
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 5-6
Elaine M. Walsh, Maccon M. Keane, David A. Wink, Grace Callagy, Sharon A. Glynn
Nuclear Factor-κB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia
Critical Reviews™ in Oncogenesis, Vol.15, 2009, issue 1-2
Astrid Marta Olsnes, Elisabeth Ersvar, Oystein Bruserud, Bjorn Tore Gjertsen, Hakon Reikvam
Resistance to Cell Death and Its Modulation in Cancer Stem Cells
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Ahmad R. Safa
Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 1
Carlos L. Arteaga, Brent N. Rexer
Targeting the Regulatory Machinery of BIM for Cancer Therapy
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Steven Grant, Hisashi Harada